Search results
Showing 16 to 19 of 19 results for amyloidosis
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)
This guidance has been updated and replaced by NICE technology appraisal guidance 984.
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.